An abstract presented at the 2023 American Society of Hematology Annual Meeting and Exposition suggests that patients with chronic lymphocytic leukemia (CLL) treated in the era of novel agents might be less likely to experience Richter transformation compared with those treated prior to this era.
Kimberly Westrich, MA, of the National Pharmaceutical Council, explained how she envisions value assessment tools to be used in the US health care system in coming years.
The most-read content from the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting including the latest findings in ongoing clinical trials, a panel discussion on Medicare oncology payment models, and the importance of alignment between clinicians and payers on clinical pathways.
Andy Blauvelt, MD, MBA, president of Oregon Medical Research Center, recommends new novel topical therapies over topical steroids for patients with atopic dermatitis (AD).
This year’s top content from the annual San Antonino Breast Cancer Symposium (SABCS) is concentrated in 3 areas: health equity, benign breast disease, and fertility preservation following diagnosis.
Our top coverage from the CHEST Annual Meeting 2023 explored various topics, including strategies to prevent air pollutant exposure and keys to achieving equity in lung cancer screenings.
The 5-year event-free survival EFS) rate was 81.3% with neoadjuvant pembrolizumab/chemotherapy followed by adjuvant pembrolizumab compared with 72.3% in those who received placebo/chemotherapy plus placebo.
Data presented at the 2023 American Society of Hematology (ASH) Annual Meeting and Exposition highlighted improvements in patient-reported outcomes (PROs) with ciltacabtagene autoleucel (cilta-cel) in multiple myeloma (MM).
The top 5 most-viewed content from the American Society for Preventive Cardiology (ASPC) Congress on Cardiovascular Disease (CVD) Prevention included interviews with Stephen Nicholls, PhD, MBBS, and Emelia J. Benjamin, MD, ScM, as well as coverage on multiple areas of cardiovascular medicine.
Key highlights from SLEEP 2023: long COVID-19's impact on sleep, racial disparities in sleep health, idiopathic hypersomnia prevalence, disrupted nighttime sleep's link to narcolepsy in children, and the ease of transitioning to lower-sodium oxybate in narcolepsy treatment while maintaining effectiveness.
The authors concluded that the data support consideration of the oral regimen of decitabine and cedazuridine to reduce the treatment burden associated with intraveous or subcutaneous hypomethylating agents in patients with myelodysplastic syndromes (MDS).
From the 2023 Academy of Managed Care Pharmacy (AMCP) Nexus meeting, held in October, expert interviews and insightful updates on the Inflation Reduction Act, gene therapy affordability and access, and the 340B Drug Pricing Program comprise the conference highlights.
Our top conference coverage of 2023 covered a range of topics, including cardiovascular disease, heart failure, breast cancer, and chronic lymphocytic leukemia.
These findings suggest that addressing socioeconomic disparities and inequities that impact access to health care and services may help improve survival outcomes across racial/ethnic groups of male patients with early breast cancer.
Our top coverage from this year’s Revolutionizing Atopic Dermatitis (RAD) conference highlighted the evolving therapy landscape for patients with AD.
Dose modifications of talquetamab improved on-target adverse effects while maintaining responses for patients with relapsed/refractory multiple myeloma.
Our most-read coverage from the Association of Community Cancer Centers (ACCC) 2023 Annual Meeting and Cancer Center Business Summit highlighted ongoing issues in oncology policy and practice.
Our most-read coverage from the 2023 European Society for Medical Oncology (ESMO) Congress included potentially practice-changing findings across a range of cancer types, including lung cancer, breast cancer, and urothelial carcinoma.
The results indicated that a substantial proportion of patients, particularly in rural, less educated, and elderly demographics, are insufficiently informed about novel MM treatments, including chimeric antigen receptor (CAR) T-cell therapies and bispecific antibody alternatives.
Our most-read coverage of American Society of Nephrology Kidney Week 2023 highlighted discussions on the challenges of medication dose adjustments in chronic kidney disease, the impact of LGBTQ+ health care disparities on kidney outcomes, and much more.
Robert Rifkin, MD, medical oncologist and hematologist at Rocky Mountain Cancer Centers, shares insight into how the phase 2 Optec study of teclistamab administration in the outpatient setting could help achieve important health equity and quality goals.
Ibrahim T. Aldoss, MD, of City of Hope Comprehensive Cancer Center, discusses the potential of revumenib in KMT2A-rearranged (KMT2Ar) acute leukemias, with pivotal results presented at the 65th Annual American Society of Hematology Annual Meeting and Exposition this week.
Our top coverage from the 72nd American College of Cardiology (ACC) Scientific Session included results from the STELLAR, CLEAR Outcomes, ACCESS, and HALO trials.
In AUGMENT-101, patients with R/R KMT2Ar acute leukemia had high overall response rates; despite being heavily pretreated, 40% were able to proceed to transplant and the KMT2Ar cohort was stopped early.
A late-breaking abstract presented at the American Society of Hematology Annual Meeting and Exposition supports the addition of subcutaneous daratumumab to standard-of-care bortezomib, lenalidomide, and dexamethasone (VRd) in patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplantation.
Our top coverage from this year’s Community Oncology Conference, hosted by the Community Oncology Alliance, included discussions around alternative payment models, shifts in the community oncology landscape in recent decades, and the need for reform in several areas.
In a packed session Monday at the 65th American Society of Hematology Annual Meeting and Exposition in San Diego, California, Anita Kumar, MD, of Memorial Sloan Kettering Cancer Center, presented phase 2 results for 25 patients with TP53 mutations.
Patients with B-cell malignancies who were intolerant to treatment with acalabrutinib experienced clinically meaningful benefits when treated with zanubrutinib, suggesting zanubrutinib may be a viable treatment option for this population.
David J. Andorsky, MD, board-certified medical oncologist and hematologist at Rocky Mountain Cancer Centers, discussed findings from a study on patterns of Bruton tyrosine kinase (BTK) inhibitor care use and social determinants of health (SDOH) among patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
Use of an antibody drug conjugate and a PD-1 inhibitor brings complementary mechanisms together while eliminating the most toxic agent that has been used in combinations to treat classic Hodgkin lymphoma (cHL).
259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512
© 2025 MJH Life Sciences®
All rights reserved.
